Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Patrick Vink, M.D., has joined the Company as Senior Vice President and General Manager of its International Business. In this new position reporting to Cubist President and COO Robert J. Perez, Dr. Vink will oversee Cubist’s commercial opportunities across Europe and in select developing markets, as well as global partnerships.
Cubist Appoints Patrick Vink as Senior Vice President and General Manager of International Business (Photo: Business Wire)
Dr. Vink brings 25 years of global industry experience to Cubist, most recently serving as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink coordinated all hospital business of the company. He joined Mylan in 2008, and established the company’s operations in Switzerland, which was the basis of a number of global functions. Dr. Vink was also responsible for the company’s biosimilars market entry.
Prior to Mylan, Dr. Vink held several leadership positions across the industry, including Head of Business Franchise Biopharmaceuticals for Novartis Sandoz; Director, Central Europe and VP International Sales for Biogen; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthelabo.
“Patrick brings extensive global experience to Cubist. His deep understanding of the international markets and strong track record of commercial success – including the launch of several blockbuster products – will be a tremendous asset to Cubist as we develop and implement our international strategy,” said Perez. “I also know Patrick to be a dynamic and insightful leader who shares Cubist’s dedication to innovation and collaboration. I am confident that he will make a great additional to our leadership team.”“This is an incredible time to be joining Cubist,” said Dr. Vink. “The company has great momentum and the wind at its back as it looks to grow its business and expand its global presence. I’m delighted to be joining the ranks of Cubist’s talented team and look forward to working with the organization to build and develop its international business.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts